Brief: Blueprint Medicines Says Expect To Achieve $2 Billion In Ayvakit Revenue By 2030
12/01/2025 21:05
Jan 12 (Reuters) - Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES PROVIDES 2025 OUTLOOK AND HIGHLIGHTS
STRATEGY FOR CONTINUED GROWTH
* BLUEPRINT MEDICINES CORP - EXPECT TO ACHIEVE $2 BILLION IN
AYVAKIT REVENUE BY 2030
Source text: ID:nPn42nM2wa
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G